Zacks Investment Research on MSN

Here's why Labcorp Holdings (LH) is a strong momentum stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Here's What to Expect From Labcorp Holdings’ Next Earnings Report

Labcorp Holdings will report its second-quarter results by the end of this month, and analysts are anticipating a ...

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered ...

Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026

Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on ...
The Daily Hodl

Healthcare Firm Handing Up to $5,000 to Patients After Data Breach Allegedly Exposes 7,700,000 People

A healthcare company is preparing to pay $35,000,000 to settle a class action lawsuit over a cybersecurity incident that ...

Labcorp rolls out colorectal cancer screening test nationwide

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains

Shares of Labcorp Holdings Inc. LH rallied 1.39% to $283.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 7,483 ...

Labcorp announces colorectal cancer test availability in US

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.
Medindia

Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...
Nasdaq

Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening ...
Business Insider

GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH

Labcorp OnDemand enables convenient testing with the NASHnext® test, within a physician-directed care pathway to support identification of patients with at-risk MASH This model expands access and ...
Morningstar

Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 ...